TY  - JOUR

T1  - Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial

JO  - Journal of Clinical Oncology

UR  - https://eprints.whiterose.ac.uk/171150/

PY  - 2020/12/01

AU  - Eisen T

AU  - Frangou E

AU  - Oza B

AU  - Ritchie AWS

AU  - Smith B

AU  - Kaplan R

AU  - Davis ID

AU  - Stockler MR

AU  - Albiges L

AU  - Escudier B

AU  - Larkin J et al

ED  - 

DO  - DOI: 10.1200/jco.20.01800

PB  - American Society of Clinical Oncology (ASCO)

VL  - 38

IS  - 34

SP  - 4064

EP  - 4075

Y2  - 2024/12/22

ER  -